TRIM21 and interstitial lung disease: As shown in our monocentric analysis on anti-Ro52 patients with idiopathic inflammatory myopathy-ILD, anti-Ro52 antibodies are strong predictors of ILD development, significantly associated with antisynthetase antibodies, as confirmed by previous findings (52, 56).